ストックスクリーナーアプリを入手
8.81
0.80%
0.07
アフターアワーズ：
8.81
前日終値:
$8.74
開ける：
$8.72
24時間の取引高:
6.73M
Relative Volume:
0.53
時価総額：
$10.34B
収益：
$14.33B
当期純損益:
$-3.79B
株価収益率:
-2.7792
EPS:
-3.17
ネットキャッシュフロー:
$1.84B
1週間 パフォーマンス:
-6.38%
1か月 パフォーマンス:
-4.03%
6か月 パフォーマンス:
-21.90%
1年 パフォーマンス:
-26.34%
1日の値動き範囲:
$8.625
$8.87
1週間の範囲:
$8.625
$9.38
52週間の値動き範囲:
$6.85
$13.55
Viatris Inc Stock (VTRS) Company Profile
VTRS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
8.81 | 10.26B | 14.33B | -3.79B | 1.84B | -3.17 |
|
ZTS
Zoetis Inc
|
147.38 | 64.91B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.16 | 43.33B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.66 | 42.36B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.38 | 17.72B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
294.28 | 12.42B | 2.99B | 1.21B | 1.13B | 25.06 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-06 | 開始されました | Goldman | Neutral |
| 2024-07-19 | 再開されました | Jefferies | Buy |
| 2023-10-23 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2023-06-23 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2023-04-24 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2023-02-17 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | アップグレード | Jefferies | Hold → Buy |
| 2022-11-10 | アップグレード | UBS | Sell → Neutral |
| 2022-11-08 | アップグレード | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | 再開されました | Jefferies | Hold |
| 2022-06-14 | 開始されました | UBS | Sell |
| 2022-05-10 | ダウングレード | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-03-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | 開始されました | Citigroup | Neutral |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2021-03-08 | ダウングレード | Goldman | Buy → Neutral |
| 2021-03-02 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-02-26 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | 開始されました | Argus | Hold |
| 2020-12-14 | 開始されました | Bernstein | Mkt Perform |
すべてを表示
Viatris Inc (VTRS) 最新ニュース
Viatris' New Fast-Acting Pain Drug Could Reduce Opioid Use: Phase 3 Data Reveals Breakthrough Results - Stock Titan
What are Viatris Inc. company’s key revenue driversStock Market Opportunities For Every Investor - jammulinksnews.com
Xanax Maker Partially Blocks Hemp Co.'s 'Canvax' TM - Law360
What makes Viatris Inc. stock attractive to long term investorsSmart Safety Strategy With Real Data Analysis - Newser
Anchoring Your Portfolio: Is VTRS Stock a Safe Harbor? - investchronicle.com
What data driven models say about Viatris Inc.’s futureHigh Return Trade Roadmap with Setup Filters - Newser
Influenza Vaccine Market is projected to grow to US$ 13.75 - openPR.com
Lidocaine Vial Market Set to Witness Significant Growth by 2033 | - openPR.com
Neurovascular Guidewires Market Outlook 2025 to 2035: Growth - openPR.com
Should I hold or sell Viatris Inc. stock in 2025Low Risk Target Finder For Every Investor - jammulinksnews.com
US Court Agrees To Throw Out Viatris Wegovy Infringement Case - insights.citeline.com
How to interpret RSI for Viatris Inc. stockMomentum Stocks with Breakout Potential - Newser
Why Viatris Inc. stock attracts strong analyst attention Daily Trade Monitor with Pattern Alerts - Newser
Why is Viatris Inc. stock attracting strong analyst attentionInvest in high-yield stocks with confidence - jammulinksnews.com
How strong is Viatris Inc. company’s balance sheetAchieve rapid financial growth with expert help - jammulinksnews.com
How does Viatris Inc. compare to its industry peersFree Bull & Bear Market Updates - jammulinksnews.com
How volatile is Viatris Inc. stock compared to the marketFree Wealth Planning Blueprint - jammulinksnews.com
What are analysts’ price targets for Viatris Inc. in the next 12 monthsPhenomenal returns - jammulinksnews.com
Competitive Positioning of Viatris Inc.: Is It Leading or LaggingFree Consultation - Newser
Why Viatris Inc. stock attracts strong analyst attentionSmart High Yield Swing Trades - metal.it
What institutions are buying Viatris Inc. stock nowConsistent double returns - jammulinksnews.com
What analysts say about Viatris Inc. stockTremendous wealth creation - PrintWeekIndia
What drives Viatris Inc. stock priceMarket-crushing profits - PrintWeekIndia
Bausch Health adds two pharmaceutical industry veterans to board By Investing.com - Investing.com Nigeria
Bausch Health Expands Leadership: Ex-Viatris CEO and Bristol Myers Legal Chief Join Board in Strategic Move - Stock Titan
Novo Nordisk defeated in Wegovy patent dispute by Viatris - Yahoo Finance
Is Viatris Inc. a good long term investmentOutperformance with explosive growth - Autocar Professional
Novo Nordisk loses Wegovy patent fight against generics maker Viatris - Endpoints News
Viatris’ Wegovy Copy Sheds One Novo Patent in Delaware Lawsuit - Bloomberg Law News
Covering The Flaws In The Viatris Undervaluation Argument (NASDAQ:VTRS) - Seeking Alpha
What to Expect From Viatris' Next Quarterly Earnings Report - MSN
What To Expect From Viatris' Next Quarterly Earnings Report - Barchart.com
VTRS Down on Late-Stage Study Failure of Eye Disease Drug - MSN
Viatris down on late-stage trial setback for eye disorder therapy - MSN
Agree To Buy Viatris At $5, Earn 3% Using Options - Nasdaq
Viatris’ blepharitis ointment fails Phase III trial - Yahoo Finance
Viatris Phase III MR-139 trial in blepharitis misses goal - The Pharma Letter
Viatris Inc. (VTRS) Stock Analysis: A Deep Dive Into Its 28% Potential Upside For Investors - DirectorsTalk Interviews
Viatris Inc. Stock Analysis and ForecastHigh-profit stock alerts - jammulinksnews.com
Viatris Announces Disappointing Phase 3 Study Results for MR-139 in Blepharitis, But Continues to Focus on Delivering Novel Therapies. - AInvest
Viatris Inc (VTRS) 財務データ
収益
当期純利益
現金流量
EPS
Viatris Inc (VTRS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Le Goff Corinne | Chief Commercial Officer |
Apr 15 '25 |
Option Exercise |
0.00 |
41,112 |
0 |
60,441 |
| FINNEY ELISHA W | Director |
Mar 04 '25 |
Option Exercise |
0.00 |
18,977 |
0 |
37,832 |
| Le Goff Corinne | Chief Commercial Officer |
Mar 04 '25 |
Option Exercise |
0.00 |
37,894 |
0 |
36,721 |
| Campbell Paul | See Remarks |
Mar 04 '25 |
Option Exercise |
0.00 |
207,325 |
0 |
328,250 |
| Campbell Paul | See Remarks |
Mar 03 '25 |
Option Exercise |
0.00 |
19,348 |
0 |
144,590 |
| Vivaldi Coelho Rogerio | Director |
Mar 04 '25 |
Option Exercise |
0.00 |
21,691 |
0 |
21,691 |
| Smith Scott Andrew | Chief Executive Officer |
Mar 04 '25 |
Option Exercise |
0.00 |
96,431 |
0 |
266,825 |
| Smith Scott Andrew | Chief Executive Officer |
Mar 03 '25 |
Option Exercise |
0.00 |
146,700 |
0 |
221,178 |
| PARRISH MARK W | Director |
Mar 04 '25 |
Option Exercise |
0.00 |
18,977 |
0 |
140,395 |
| Lyons Dillon JoEllen | Director |
Mar 04 '25 |
Option Exercise |
0.00 |
18,977 |
0 |
77,691 |
1.97%
0.53%
大文字化:
|
ボリューム (24 時間):